Foster Rx Systems Inc. provides a governed AI infrastructure called ANGIS that generates cryptographically signed, audit‑trail‑backed intelligence for regulated biopharma decisions. The platform offers two products—Thesis Rx for innovators evaluating their own clinical assets and Capital Rx for investors assessing external assets—ensuring outputs meet strict reproducibility and regulatory standards. This enables biotech, pharma, and investment teams to defend AI‑driven decisions to regulators, boards, and stakeholders.
Funding
Funding not disclosed
Founders
Product
Problem
Biopharma teams and investors need AI-driven insights to evaluate clinical assets, but existing AI tools lack auditability, reproducibility, and regulatory defensibility, exposing organizations to compliance and investment risks.
Solution
Foster Rx provides a governed AI infrastructure built on its proprietary ANGIS engine, which orchestrates multi‑agent pipelines and applies a multi‑layer governance framework to generate intelligence outputs that are cryptographically signed and linked to an immutable audit trail. The platform offers two tailored products: Thesis Rx for innovators such as academic researchers, biotech companies, and pharma business‑development teams evaluating their own assets, and Capital Rx for investors—including venture capital, hedge funds, and healthcare angels—assessing external assets. Each output can be verified against a published trust anchor, enabling users to defend AI‑in‑the‑loop decisions to regulators, boards, and limited partners. By combining governed AI analysis with verifiable provenance, Foster Rx bridges the gap between curated data feeds and ungoverned generic AI models, reducing hidden risk in regulated decision‑making.
Target Audience
Primary customers are biopharma innovators—academic translational researchers, early‑ and mid‑stage biotech firms, and pharma business‑development teams—and investment groups such as venture capital firms, hedge funds, growth equity funds, and healthcare‑focused angels evaluating clinical assets.
Features
- ANGIS engine delivering multi‑layer governance, multi‑agent orchestration, and provenance‑linked AI outputs
- Cryptographic signing of every intelligence artifact for immutable verification
- Built‑in audit‑trail generation that satisfies regulatory inspection requirements
- Separate product suites (Thesis Rx and Capital Rx) optimized for asset developers and investors
- Compatibility with existing biopharma data sources while providing governed AI analysis
- Patent‑pending architecture (US Patent No. 19/459,855) ensuring proprietary protection